// App-Quantinova.ai

4019 : A phase II, double-blind study of galunisertib+gemcitabine (GG) vs gemcitabine+placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC).

Researchers

Presenter

  • Davide Melisi

Principal Investigators

  • Rocio Garcia-Carbonero

  • Teresa Macarulla

  • Denis Pezet

  • Gael Deplanque

  • Martin Fuchs

  • Jorg Trojan

  • Helmut Oettle

  • Mark Kozloff

  • Ann Cleverly

  • Ivelina Gueorguieva

  • Durisala Desaiah

  • Michael M. F. Lahn

  • Al Blunt

  • Karim A. Benhadji

  • Josep Tabernero

Medical Centers

  • Digestive Molecular Clinical Oncology, University of Verona, Verona, Italy

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • CHU, Clermond-Ferrand, France

  • Medical Oncology, CHUV, Lausanne, Switzerland

  • Klinikum Bogenhausen, Stadtisches Klinikum Munchen GmbH, Munich, Germany

  • Goethe University Medical Center, Frankfurt, Germany

  • Onkologische und Hamatologische Schwerpunkpraxis, Friedrichshafen, Germany

  • Ingalls Memorial Hospital, Harvey, IL

  • Eli Lilly and Company, Erl Wood, United Kingdom

  • Eli Lilly and Company, Indianapolis, IN

  • Covance, Inc., Princeton, NJ

  • Lilly France, Paris, France

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

Locations

  • Italy

  • Spain

  • Germany

  • Switzerland

  • United Kingdom

  • United States

  • France

Companies

  • EMB Statistical Solu

  • Eli Lilly and Compan

  • Covance Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreatic cancer

Biomarkers

  • N/A

Drug/Treatment

  • LY2157299

  • Gemcitabine

Outcome

  • Positive

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • II

Study Id's

  • NCT01373164

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved